WOBURN, Mass. — November 7, 2025 — Leads & Copy — Neurogastrx, Inc. presented data from its Phase 2 clinical study of NG101 (metopimazine mesylate) at ObesityWeek® 2025, demonstrating a significant reduction in nausea and vomiting associated with GLP-1 agonist use.
The placebo-controlled study revealed that patients receiving NG101 experienced a 40% reduction in nausea incidence and a 67% reduction in vomiting incidence. The oral presentation at ObesityWeek® 2025 highlighted NG101’s ability to decrease the incidence, duration, and severity of these side effects commonly associated with GLP-1 agonists.
Dr. Sean Wharton, Medical Director at Wharton Medical Clinic for Weight and Diabetes Management in Ontario, Canada, noted that the GI side effects of nausea and vomiting are often unbearable for patients on GLP-1 agonists, leading to treatment discontinuation. He believes NG101 could make these medications tolerable for many patients.
The study involved 90 participants aged 18-55, who received a single 0.5 mg subcutaneous dose of semaglutide along with either 20 mg of NG101 twice daily (BID) or a placebo for five days. Results showed that NG101 significantly:
* Reduced nausea incidence by 40% (p=0.0203)
* Decreased vomiting incidence by 67% (p=0.0274) and the number of discrete vomiting episodes by 56% (p=0.0238)
* Reduced the duration of nausea and vomiting (p=0.0063); events lasting more than one day occurred in 22% vs. 51% of participants with NG101 vs. placebo
* Decreased nausea severity by 70% (p=0.0138) based on participant reports
The study also indicated an improved safety profile with fewer adverse events when semaglutide is co-administered with NG101. Participant-reported outcomes (PROs) showed that NG101 reduced the maximum nausea rating of moderate-severe nausea by 31% (p=0.0225). The FDA prioritizes PRO measures for nausea and vomiting as they more accurately reflect the participant experience.
Jim O’Mara, president and CEO of Neurogastrx, stated that GLP-1-induced nausea and vomiting prevent millions from realizing the full benefits of these medicines. He emphasized that the real-world incidence of these side effects is more significant than reported in clinical trials. O’Mara believes the reductions in nausea and vomiting with NG101, combined with its safety profile, support its further clinical development and evaluation with multiple GLP-1 treatments.
A study in JAMA Network Open revealed a 64.8% one-year discontinuation rate of GLP-1 receptor agonists (liraglutide, semaglutide, or tirzepatide) for patients without type 2 diabetes, with GI events being the primary reason. Neurogastrx estimates the GLP-1 market at $63 billion in 2025, highlighting significant losses due to these side effects.
NG101 is a peripherally acting dopamine D2 receptor antagonist. It selectively targets the Area Postrema (AP), which is outside the blood-brain barrier and rich in dopamine D2 receptors, to block the symptoms of nausea and vomiting triggered by GLP-1 agonists.
Details on the Phase 2 clinical study design can be found on www.clinicaltrials.gov (NCT06500429).
Amanda Breeding
Scient PR
amanda@scientpr.com
Source: Neurogastrx, Inc.
